Analyzing the Safety Data of JAK Inhibitors

February 12, 2025

Ryan Haumschild, PharmD, MS, MBA
Amy McMichael, MD

Opinion

Video

Panelists discuss the key safety data observed with each of the three Janus kinase (JAK) inhibitors for alopecia areata (AA), highlighting potential adverse effects and how these impact clinical decision-making.

EP: 1.Discussing the Pathophysiology of Alopecia Areata

EP: 2.Epidemiology Associated With Alopecia Areata

EP: 3.Common Comorbidities Associated With Alopecia Areata

EP: 4.Hallmark Symptoms Seen With Alopecia Areata

EP: 5.Psychosocial Impact of Alopecia Areata

EP: 6.Diagnosis of Alopecia Areata

EP: 7.Multimodal Care for Patients With Alopecia Areata

EP: 8.Deciding When to Treat Patients With Alopecia Areata

EP: 9.Choosing an Initial Therapy for Alopecia Areata

EP: 10.Adherence to Alopecia Areata Therapies

EP: 11.Adverse Events Associated With Conventional Alopecia Areata Therapies

EP: 12.Exploring Guidelines for Alopecia Areata

EP: 13.Unmet Needs for the Management of Alopecia Areata

EP: 14.Discussing Baricitinib for Alopecia Areata

EP: 15.Highlighting Deuruxolitinib for Alopecia Areata

EP: 16.Exploring Ritlecitinib for Alopecia Areata

Now Viewing

EP: 17.Analyzing the Safety Data of JAK Inhibitors

Video content above is prompted by the following:

Mostaghimi: Please discuss key safety data seen with each of the 3 JAK inhibitors.